{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:43:53Z","timestamp":1792748633203,"version":"4.5.0"},"reference-count":48,"publisher":"American Chemical Society (ACS)","issue":"20","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"name":"Guizhou Provincial Basic Research Program","award":["MS (2026) 997"],"award-info":[{"award-number":["MS (2026) 997"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171973"],"award-info":[{"award-number":["82171973"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171980"],"award-info":[{"award-number":["82171980"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zunyi Science and Technology Cooperation Project","award":["HZ (2024) 195"],"award-info":[{"award-number":["HZ (2024) 195"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This study evaluated the preclinical performance of a novel 89Zr-labeled anti-Nectin-4 monoclonal antibody, [89Zr]Zr-DFO-MW282, for PET imaging of bladder urothelial carcinoma (BUC). [89Zr]Zr-DFO-MW282 was prepared via p-isothiocyanatobenzyl-desferrioxamine (p-NCS-Bn-DFO) conjugation, achieving a radiolabeling yield exceeding 70%, radiochemical purity \u226595% post-purification, and specific activity of 36.10\u221263.72 GBq\/\u03bcmol. [89Zr]Zr-DFO-MW282 selectively accumulated in Nectin-4-positive cells and tumors, with uptake blocked by the unlabeled MW282 antibody. Small-animal PET\/CT imaging revealed sustained tumor uptake in SW780 xenografts, with a high SUVmean value of 4.46 \u00b1 0.02 at 120 h p.i. Owing to hepatobiliary clearance, the kidney and bladder uptake was minimal, yielding excellent imaging contrast. The probe demonstrated high specificity, prolonged tumor retention, and negligible bladder background, making it a promising immuno-PET probe for precise imaging of BUC and warranting further clinical translation.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6c01979","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:01:53Z","timestamp":1791223313000},"page":"24388-24399","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical Evaluation of 89Zr-Labeled Anti-Nectin-4 Antibody for Enhanced PET Imaging in Bladder Urothelial Carcinoma"],"prefix":"10.1021","volume":"69","author":[{"given":"Ya\u2019nan","family":"Ren","sequence":"first","affiliation":[{"name":"Affiliated Hospital of Zunyi Medical University , , , ,","place":["Zunyi, Guizhou, China, 563000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teli","family":"Liu","sequence":"additional","affiliation":[{"name":"Peking University Cancer Hospital & Institute , , ,","place":["Beijing, China, 100142"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingguo","family":"Hou","sequence":"additional","affiliation":[{"name":"Peking University Cancer Hospital & Institute , , ,","place":["Beijing, China, 100142"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yao","sequence":"additional","affiliation":[{"name":"Peking University Cancer Hospital & Institute , , ,","place":["Beijing, China, 100142"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Wang","sequence":"additional","affiliation":[{"name":"Peking University Cancer Hospital & Institute , , ,","place":["Beijing, China, 100142"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4492-3224","authenticated-orcid":true,"given":"Lei","family":"Xia","sequence":"additional","affiliation":[{"name":"Peking University Cancer Hospital & Institute , , ,","place":["Beijing, China, 100142"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Liu","sequence":"additional","affiliation":[{"name":"Peking University Cancer Hospital & Institute , , ,","place":["Beijing, China, 100142"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Wang","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Zunyi Medical University , , , ,","place":["Zunyi, Guizhou, China, 563000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Cai","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Zunyi Medical University , , , ,","place":["Zunyi, Guizhou, China, 563000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfeng","family":"Pan","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Zunyi Medical University , , , ,","place":["Zunyi, Guizhou, China, 563000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhu","sequence":"additional","affiliation":[{"name":"Peking University Cancer Hospital & Institute , , ,","place":["Beijing, China, 100142"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2084-5193","authenticated-orcid":true,"given":"Zhi","family":"Yang","sequence":"additional","affiliation":[{"name":"Peking University Cancer Hospital & Institute , , ,","place":["Beijing, China, 100142"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"issue":"3","key":"2026102305092097700_cit1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"74","author":"Bray","year":"2024","journal-title":"Ca-Cancer J. Clin."},{"issue":"12","key":"2026102305092097700_cit2","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s41585-025-01072-0","article-title":"Low-Grade Non-Muscle-Invasive Bladder Cancer: Molecular Landscape, Treatment Strategies and Emerging Therapies","volume":"22","author":"Wen","year":"2025","journal-title":"Nat. Rev. Urol."},{"issue":"1","key":"2026102305092097700_cit3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur. Urol."},{"issue":"4","key":"2026102305092097700_cit4","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3390\/ijms20040821","article-title":"Bladder Cancer Diagnosis and Follow-Up: The Current Status and Possible Role of Extracellular Vesicles","volume":"20","author":"Oeyen","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"2026102305092097700_cit5","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/nejmoa1801993","article-title":"MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"2026102305092097700_cit6","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.can-15-1313","article-title":"Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res."},{"issue":"6","key":"2026102305092097700_cit7","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s00428-025-04164-9","article-title":"Nectin-4 Expression in Upper and Lower Tract Urothelial Carcinoma: Correlation with Early-Stage Disease and Prognostic Relevance","volume":"488","author":"Kobayashi","year":"2026","journal-title":"Virchows Arch."},{"key":"2026102305092097700_cit8","doi-asserted-by":"publisher","first-page":"216606","DOI":"10.1016\/j.canlet.2023.216606","article-title":"Near-Infrared Photoimmunotherapy Targeting Nectin-4 in a Preclinical Model of Bladder Cancer","volume":"585","author":"Fukushima","year":"2024","journal-title":"Cancer Lett."},{"issue":"1","key":"2026102305092097700_cit9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/jco.22.01643","article-title":"Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"2026102305092097700_cit10","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/nejmoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"29","key":"2026102305092097700_cit11","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1\/Programmed Death Ligand 1 Therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"2026102305092097700_cit12","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1158\/1535-7163.mct-22-0743","article-title":"Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-Based Antibody-Drug Conjugate for Treatment of Nectin-4-Expressing Cancers","volume":"22","author":"Zhou","year":"2023","journal-title":"Mol. Cancer Ther."},{"issue":"16_suppl","key":"2026102305092097700_cit13","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1200\/jco.2024.42.16_suppl.3013","article-title":"9MW2821, a Nectin-4 Antibody-Drug Conjugate (ADC), in Patients with Advanced Solid Tumor: Results from a Phase 1\/2a Study","volume":"42","author":"Zhang","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"2026102305092097700_cit14","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/nejmoa2035807","article-title":"Enfortumab Vedotin Inpreviously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"2026102305092097700_cit15","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1158\/1078-0432.ccr-22-1764","article-title":"Membranous NECTIN-4 Expression Frequently Decreases During Metastatic Spread of Urothelial Carcinoma and is Associated with Enfortumab Vedotin Resistance","volume":"29","author":"Klu\u0308mper","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"20","key":"2026102305092097700_cit16","doi-asserted-by":"publisher","first-page":"21962","DOI":"10.1021\/acs.jmedchem.5c02371","article-title":"Precision on Two Wheels\ue5f8Structural Refinement of 64Cu- and 68Ga-Labeled Bicyclic Peptides Targeting Nectin-4 for Improved Tumor Imaging: From Preclinical Development to First-in-Human Application","volume":"68","author":"Kro\u0308nke","year":"2025","journal-title":"J. Med. Chem."},{"issue":"9","key":"2026102305092097700_cit17","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.1021\/acs.molpharmaceut.4c00366","article-title":"Effects of PEGylation on Imaging Contrast of 68Ga-Labeled Bicyclic Peptide PET Probes Targeting Nectin-4","volume":"21","author":"Wan","year":"2024","journal-title":"Mol. Pharm."},{"key":"2026102305092097700_cit18","doi-asserted-by":"publisher","first-page":"107745","DOI":"10.1016\/j.bioorg.2024.107745","article-title":"A Cutting-Edge 68Ga-Labeled Bicyclic Peptide PET Molecular Probe for Noninvasive Assessment of Nectin4 Expression","volume":"152","author":"Ge","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"17","key":"2026102305092097700_cit19","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1158\/1078-0432.ccr-23-0609","article-title":"First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET\/CT Imaging of Advanced Urothelial Carcinoma","volume":"29","author":"Duan","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"17","key":"2026102305092097700_cit20","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1158\/1078-0432.ccr-23-1243","article-title":"PET Imaging of Nectin-4: A Promising Tool for Personalized\/Precision Oncology","volume":"29","author":"Jiang","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"2026102305092097700_cit21","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s12951-026-04253-0","article-title":"68Ga\/177Lu-Labeled Nectin4-Targeted Covalent Bicyclic Peptide: A Novel Nectin-4-Targeted Radioligands for Theranostic of Urothelial Carcinoma","volume":"24","author":"Sun","year":"2026","journal-title":"J. Nanobiotechnol."},{"issue":"8","key":"2026102305092097700_cit22","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1007\/s00259-018-3941-3","article-title":"ImmunoPET Imaging of CD38 in Murine Lymphoma Models Using 89Zr-Labeled Daratumumab","volume":"45","author":"Kang","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"2026102305092097700_cit23","doi-asserted-by":"publisher","first-page":"592","DOI":"10.2967\/jnumed.124.268387","article-title":"225Ac\/89Zr-Labeled N4MU01 Radioimmunoconjugates as Theranostics Against Nectin-4\u2212Positive Triple-Negative Breast Cancer","volume":"66","author":"Babeker","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"12","key":"2026102305092097700_cit24","doi-asserted-by":"publisher","first-page":"110816","DOI":"10.1016\/j.jbc.2025.110816","article-title":"Structural Basis of Nectin-4 Recognition by the Antibody-Drug Conjugate 9MW2821","volume":"301","author":"Fang","year":"2025","journal-title":"J. Biol. Chem."},{"issue":"3","key":"2026102305092097700_cit25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.2967\/jnumed.125.271103","article-title":"Nectin-4-Targeted Radiotheranostics for Personalized Cancer Therapy: A Systematic Review","volume":"67","author":"Scha\u0308fer","year":"2026","journal-title":"J. Nucl. Med."},{"issue":"1","key":"2026102305092097700_cit26","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12951-022-01444-3","article-title":"Nectin-4-Targeted immunoSPECT\/CT Imaging and Photothermal Therapy of Triple-Negative Breast Cancer","volume":"20","author":"Shao","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"2026102305092097700_cit27","doi-asserted-by":"publisher","first-page":"123756","DOI":"10.1016\/j.ijpharm.2023.123756","article-title":"An Iodine-Labelled Antibody-Drug Conjugate PET Probe for Noninvasive Monitoring of Nectin-4 Expression in Urothelial Carcinoma","volume":"651","author":"Ren","year":"2024","journal-title":"Int. J. Pharm."},{"issue":"5","key":"2026102305092097700_cit28","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s11307-016-0953-x","article-title":"Preclinical Evaluation of an Anti-Nectin-4 immunoPET Reagent in Tumor-Bearing Mice and Biodistribution Studies in Cynomolgus Monkeys","volume":"18","author":"Campbell","year":"2016","journal-title":"Mol. Imaging Biol."},{"issue":"1","key":"2026102305092097700_cit29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.nucmedbio.2012.08.004","article-title":"PET Imaging with 89Zr: from Radiochemistry to the Clinic","volume":"40","author":"Deri","year":"2013","journal-title":"Nucl. Med. Biol."},{"issue":"5","key":"2026102305092097700_cit30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and Challenges for the Next Generation of Antibody-Drug Conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"4","key":"2026102305092097700_cit31","first-page":"147","article-title":"Evaluation of Enhanced Permeability Effect and Different Linear Energy Transfer of Radionuclides in a Prostate Cancer Xenograft Model","volume":"13","author":"Vilhelmsson Timmermand","year":"2023","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"2026102305092097700_cit32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13550-024-01079-5","article-title":"Non-Specific Irreversible 89Zr-mAb Uptake in Tumours: Evidence from Biopsy-Proven Target-Negative Tumours Using 89Zr-Immuno-PET","volume":"14","author":"Wijngaarden","year":"2024","journal-title":"EJNMMI Res."},{"issue":"1","key":"2026102305092097700_cit33","doi-asserted-by":"publisher","first-page":"162","DOI":"10.2967\/jnumed.116.177857","article-title":"Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab","volume":"58","author":"England","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"10","key":"2026102305092097700_cit34","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.mayocp.2015.07.011","article-title":"Answers to Common Questions About the Use and Safety of CT Scans","volume":"90","author":"McCollough","year":"2015","journal-title":"Mayo Clin. Proc."},{"issue":"1","key":"2026102305092097700_cit35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2967\/jnumed.117.194555","article-title":"Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer","volume":"59","author":"O\u2019Donoghue","year":"2018","journal-title":"J. Nucl. Med."},{"issue":"1","key":"2026102305092097700_cit36","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3390\/cells15010073","article-title":"Preclinical PET and SPECT Imaging in Small Animals: Technologies, Challenges and Translational Impact","volume":"15","author":"Bruzgo-Grzybko","year":"2025","journal-title":"Cells"},{"issue":"5","key":"2026102305092097700_cit37","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1021\/acs.molpharmaceut.5c00193","article-title":"Radiosynthesis and Evaluation of a Novel 68Ga-Labeled Peptide for PD-L1-Targeted PET Imaging","volume":"22","author":"Zhang","year":"2025","journal-title":"Mol. Pharm."},{"issue":"13","key":"2026102305092097700_cit38","doi-asserted-by":"publisher","first-page":"14019","DOI":"10.1021\/acs.jmedchem.5c01163","article-title":"Development of Cysteic Acid-Modified FAP Radioligands for Enhanced Renal Clearance: From Preclinical Optimization to First-in-Human Study","volume":"68","author":"Peng","year":"2025","journal-title":"J. Med. Chem."},{"issue":"4","key":"2026102305092097700_cit39","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1080\/21681805.2017.1321579","article-title":"[18F]Fluorodeoxyglucose-Positron Emission Tomography\/Computed Tomography Response Evaluation Can Predict Histological Response at Surgery After Induction Chemotherapy for Oligometastatic Bladder Cancer","volume":"51","author":"Kollberg","year":"2017","journal-title":"Scand. J. Urol."},{"key":"2026102305092097700_cit40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.nucmedbio.2019.01.010","article-title":"Dual-Isotope Imaging Allows In Vivo Immunohistochemistry Using Radiolabelled Antibodies in Tumours","volume":"70","author":"Knight","year":"2019","journal-title":"Nucl. Med. Biol."},{"issue":"27","key":"2026102305092097700_cit41","doi-asserted-by":"publisher","first-page":"12369","DOI":"10.1073\/pnas.0913667107","article-title":"Paradoxical Glomerular Filtration of Carbon Nanotubes","volume":"107","author":"Ruggiero","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"4","key":"2026102305092097700_cit42","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/j.semnuclmed.2012.02.002","article-title":"Positron Emission Tomography in Renal Cell Carcinoma: An Imaging Biomarker in Development","volume":"42","author":"Khandani","year":"2012","journal-title":"Semin. Nucl. Med."},{"issue":"Supplement 1","key":"2026102305092097700_cit43","doi-asserted-by":"publisher","first-page":"12s","DOI":"10.2967\/jnumed.123.266830","article-title":"Translational PET Imaging of Nectin-4 Expression in Multiple Different Cancers with 68Ga-N188","volume":"65","author":"Zhang","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"12","key":"2026102305092097700_cit44","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.7150\/thno.84865","article-title":"Click-to-Release: Cleavable Radioimmunoimaging with [89Zr]Zr-DFO-Trans-Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio","volume":"13","author":"Vlastara","year":"2023","journal-title":"Theranostics"},{"issue":"1","key":"2026102305092097700_cit45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13550-018-0358-8","article-title":"Assessment of Target-Mediated Uptake with Immuno-PET: Analysis of a Phase I Clinical Trial with an Anti-CD44 Antibody","volume":"8","author":"Jauw","year":"2018","journal-title":"EJNMMI Res."},{"issue":"1","key":"2026102305092097700_cit46","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13550-023-01030-0","article-title":"Fc-Engineered Monoclonal Antibodies to Reduce Off-Target Liver Uptake","volume":"13","author":"Mangeat","year":"2023","journal-title":"EJNMMI Res."},{"key":"2026102305092097700_cit47","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41586-026-10789-w","article-title":"Modular In Vivo Antibody\u2212ADC Click to Reverse Drug Resistance in Tumours","volume":"657","author":"Simo\u0301","year":"2026","journal-title":"Nature"},{"issue":"1","key":"2026102305092097700_cit48","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ymeth.2013.09.015","article-title":"Engineered Antibodies for Molecular Imaging of Cancer","volume":"65","author":"Wu","year":"2014","journal-title":"Methods"}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6c01979","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/20\/24388\/68749470\/jm6c01979.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/20\/24388\/68749470\/jm6c01979.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:25:45Z","timestamp":1792747545000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/20\/24388\/5444782\/Preclinical-Evaluation-of-89Zr-Labeled-Anti-Nectin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":48,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2026,10,5]]},"published-print":{"date-parts":[[2026,10,22]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c01979","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]}}}